Company Profile

Industry Sector: Medical Devices

Company Overview: IBI is developing a drug which blocks pore-forming toxins, specifically α-toxin, a key virulence factor of MRSA.

- Secured $1.8 million NIH grant funding
- $200,000 from CIT BioLife Fund and Johnson & Johnson
- USAMRIID Anthrax collaboration
- Method and pharmaceutical composition patents

Target Market(s): Methicillin-resistant Staphylococcus aureus Infection (MRSA).

- 20,000 deaths in the US from MRSA in 2008
- Will become the third leading cause of death in the US within 5 years.
- 85% of MRSA Infections are acquired in the hospital.
- Everyone is at risk.

Development Timeline

How We Combat MRSA

Investment Summary

Investment Summary:

- $2 million – 2 candidates – patents – leading edge science
- Know what we have to do to achieve objectives
- Executing faster and cheaper
- Seeking Series A financing of $5 to $7 million
- Exit transaction with pharma partner in 24 to 36 months